Cannabis Watch: GW Pharma shares rally on earnings and news of late-stage trial of cannabis-based treatment for MS patients
Shares of GW Pharmaceuticals PLC jumped 18% Tuesday, after the biotech posted a narrower-than-expected third-quarter loss and a revenue beat and said a delayed late-stage trial of its cannabinoid-based treatment for multiple sclerosis spasticity can now proceed.
